research use only
Cat.No.S1229
| Related Targets | HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA/RNA Synthesis Inhibitors | CX-5461 (Pidnarulex) B02 SCR7 Favipiravir (T-705) EED226 BMH-21 RK-33 Triapine (3-AP) Carmofur YK-4-279 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HL60 cells | Proliferation assay | 48 h | Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.09 μM | |||
| MCF7 cells | Proliferation assay | 48 h | Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.13 μM | |||
| KG1 cells | Proliferation assay | 48 h | Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.15 μM | |||
| Raji cells | Proliferation assay | 48 h | Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.4 μM | |||
| K562 cells | Proliferation assay | 48 h | Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.4 μM | |||
| ZR-75-1 cells | Proliferation assay | 48 h | Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.6 μM | |||
| MOLT3 cells | Proliferation assay | 48 h | Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=0.95 μM | |||
| M-HeLa cells | Proliferation assay | 48 h | Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=2 μM | |||
| SK-UT-1B cells | Proliferation assay | 48 h | Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay, IC50=6 μM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 73 mg/mL
(199.88 mM)
Water : 3 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 365.21 | Formula | C10H13FN5O7P |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 75607-67-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | F-ara-A Phosphate, NSC 118218 Phosphate | Smiles | C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N | ||
| Targets/IC50/Ki |
DNA polymerase α
(Cell-free assay) 1.1 μM(Ki )
DNA polymerase δ
(Cell-free assay) 1.3 μM(Ki)
|
|---|---|
| In vitro |
Fludarabine Phosphate is converted to F-ara-ATP in cells and then incorporated into DNA in a self-limiting manner. This compound competes with dATP for incorporation into the A site of the extending DNA strand, which results in termination of DNA strand elongation. Human DNA polymerase α incorporates more of this chemical into DNA than polymerase δ. It completively inhibits DNA polymerase α and DNA polymerase δ with Ki of 1.1 μM and 1.3 μM, respectively. DNA polymerase δ is also able to excise the incorporated Fludarabine Phosphate from DNA in vitro.
|
| In vivo |
Fludarabine Phosphate is toxic for tumor-free mice. The maximum tolerated dose (LD10) of this compound administered as a single dose is 234 mg/kg. The 50% lethal dose is 375 mg/kg. This chemical administered as a single dose induces fewer number of cells surviving therapy in mice bearing P388 leukemia, accompanied by greater percentage of increase in life span (110%) and increased median survival time.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05039892 | Not yet recruiting | CholangiocarcinomaAdult |
3D Medicines (Beijing) Co. Ltd.|3D Medicines |
December 2024 | Phase 2 |
| NCT06377293 | Not yet recruiting | End-Stage Kidney Disease |
Far Eastern Memorial Hospital |
November 2024 | Not Applicable |
| NCT06398002 | Not yet recruiting | Secondary Hyperparathyroidism|End-stage Kidney Disease |
Iain Bressendorff|Herlev Hospital |
August 1 2024 | Phase 2 |
| NCT06383403 | Not yet recruiting | Primary Biliary Cholangitis |
Ipsen |
July 1 2024 | Phase 3 |
| NCT06302439 | Not yet recruiting | Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency|ATP-Binding Cassette Subfamily C Member 6 Deficiency |
Inozyme Pharma|GACI Global |
May 2024 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.